| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1K | — | — |
| R&D Expense | $1.2M | — | +97.2% |
| SG&A Expense | $706K | — | +68.6% |
| Operating Income | -$1.9M | — | -85.6% |
| Net Income | -$1.6M | — | +23.8% |
| EPS (Basic) | $0.00 | — | — |
| EPS (Diluted) | $0.00 | — |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $33.5M | -3.4% | -17.4% |
| Short-term Investments | $2.0M | -34.0% | — |
| Accounts Receivable | $1K | — | — |
| Current Assets | $35.5M | -5.8% | -17.6% |
| Total Assets | $35.7M | -5.8% | -17.6% |
| Total Liabilities | $767K |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.2M | — | -68.5% |
| Investing Cash Flow | $1.0M | — | — |
| Financing Cash Flow | -$1.0M | — | -146.2% |
| +13.6% |
| +30.7% |
| Stockholders' Equity | $34.5M | -5.8% | -17.8% |